Rezultati

eNauka >  Results >  Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
Title: Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
Authors: Syrigos, Konstantinos; Abert, Istvan; Andric, Zoran G  ; Bondarenko, Igor N; Dvorkin, Mikhail; Galic, Kristina; Galiulin, Rinat; Kuchava, Vladimer; Sriuranpong, Virote; Trukhin, Dmytro;
Zhavrid, Edvard; Fu, Dongyue; Kassalow, Laurent M; Jones, Stephanie; Bashir, Zahid;
Issue Date: 2021
Publication: BIODRUGS
ISSN: 1173-8804 Biodrugs Search Idenfier
Type: Article
Collation: vol. 35 br. 4 str. 417-428
DOI: 10.1007/s40259-021-00489-4
WoS-ID: 000673887100001
Scopus-ID: 2-s2.0-85110201901
PMID: 34264503
PMCID: PMC8295151
URI: https://enauka.gov.rs/handle/123456789/805562
Project: Centus Biotherapeutics
Metadata source: (Preuzeto iz Nasi u WoS)
M-category: 
21aM21a

22
SCOPUSTM
14
PubMed CentralTM
5
OpenCitations
17
WEB OF SCIENCETM
Alt metrika
Dimensions
Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.